Citigroup Inc Seagen Inc. Transaction History

Citigroup Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$191.51 - $216.16 $6 Million - $6.77 Million	31,307 Added 11.98%	292,589 $62.1 Million
Q2 2023 Aug 10, 2023	BUY	$187.64 - $206.25 $18.1 Million - $19.9 Million	96,269 Added 58.34%	261,282 $50.3 Million
Q1 2023 May 11, 2023	BUY	$127.59 - $203.08 $2.24 Million - $3.56 Million	17,527 Added 11.88%	165,013 $33.4 Million
Q4 2022 Feb 09, 2023	SELL	$117.37 - $139.17 $13 Million - $15.5 Million	-111,117 Reduced 42.97%	147,486 $19 Million
Q3 2022 Nov 10, 2022	BUY	$135.27 - $180.11 $21.7 Million - $29 Million	160,752 Added 164.28%	258,603 $35.4 Million
Q2 2022 Aug 10, 2022	SELL	$108.81 - $179.33 $4.6 Million - $7.58 Million	-42,280 Reduced 30.17%	97,851 $17.3 Million
Q1 2022 May 12, 2022	SELL	$119.61 - $157.85 $5.36 Million - $7.07 Million	-44,786 Reduced 24.22%	140,131 $20.2 Million
Q4 2021 Feb 10, 2022	BUY	$142.57 - $190.86 $13.4 Million - $18 Million	94,241 Added 103.93%	184,917 $28.6 Million
Q3 2021 Nov 10, 2021	BUY	$142.45 - $169.82 $12.9 Million - $15.4 Million	90,676 New	90,676 $15.4 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.